home / stock / ikt / ikt news

IKT News and Press, Inhibikase Therapeutics Inc. From 10/16/23

Stock Information
Company Name: Inhibikase Therapeutics Inc.
Stock Symbol: IKT
Market: NASDAQ
Website: inhibikase.com
Menu
IKT IKT Quote IKT Short IKT News IKT Articles IKT Message Board
Get IKT Alerts

News, Short Squeeze, Breakout and More Instantly...
IKT - Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

BOSTON and ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PD”), Parkinson&#x...
IKT - BTAI, SXTC and FRLN among pre-market losers

2023-10-05 08:16:47 ET More on BioXcel Therapeutics, Lithium Americas Corp., etc. Lithium Americas (Argentina): An Outrageously Undervalued Lithium Company BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel's Struggles: From FDA Issues To F...

IKT - EBIX, BTAI and TSE among mid-day movers

2023-10-04 13:55:53 ET Gainers: Vivos Therapeutics ( VVOS ) +111% . Nuvalent ( NUVL ) +30% . Spectral AI ( MDAI ) +27% . Gaucho Group Holdings ( VINO ) +25% . Gritstone Bio ( GRTS ) +19% . BioXcel Therapeutics ( BTAI ) ...

IKT - Bioline Rx, Accuray among healthcare movers

2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...
IKT - Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and...

IKT - BIOL, AXLA and IKT among mid-day movers

2023-09-20 12:56:40 ET Gainers: MSP Recovery ( LIFW ) +124% . Digital Transformation Opportunities Corp. ( DTOC ) +121% . Bluejay Diagnostics ( BJDX ) +41% . EBET ( EBET ) +33% . Solowin Holdings ( SWIN ) +24% . Steelcase ( ...

IKT - CLIR, CETX and APLT among mid-day movers

2023-09-19 13:01:28 ET Gainers: Connexa Sports Technologies ( CNXA ) +170% . Davis Commodities Limited Ordinary Shares ( DTCK ) +83% . Maplebear ( CART ) +40% . Avinger ( AVGR ) +40% . Rackspace Technology ( RXT ) +37% . Elut...
IKT - Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib PR Newswire - New tablet formulation of risvodetinib approximately doubles drug exposure at same dose – - Tablet formulation to be evaluated in the planned 12-month extension port...

IKT - Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib PR Newswire - Company to assess new molecules arising from internal discovery and other companies to enhance suppression of neurodegeneration through c-...

IKT - Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro PR Newswire - 600 mg IkT-001Pro demonstrated bioequivalence to Standard-of-Care 400 mg Dose of Imatinib mesylate - - Minimal adverse events with consistent drug delivery see...
Previous 10 Next 10